|
JP5592792B2
(ja)
|
2007-09-26 |
2014-09-17 |
ユセベ ファルマ ソシエテ アノニム |
二重特異性抗体の融合体
|
|
LT2334705T
(lt)
*
|
2008-09-26 |
2017-03-27 |
Ucb Biopharma Sprl |
Biologiniai produktai
|
|
EP2398498B1
(en)
|
2009-02-17 |
2018-09-05 |
UCB Biopharma SPRL |
Antibody molecules having specificity for human ox40
|
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
TW201106971A
(en)
*
|
2009-05-28 |
2011-03-01 |
Glaxo Group Ltd |
Antigen-binding proteins
|
|
JP5901517B2
(ja)
*
|
2009-05-28 |
2016-04-13 |
グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ |
抗原結合性タンパク質
|
|
US20120134984A1
(en)
*
|
2009-06-01 |
2012-05-31 |
Olga Lubman |
Molecules with extended half-lives and uses thereof
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
ES2667258T3
(es)
*
|
2009-09-10 |
2018-05-10 |
Ucb Biopharma Sprl |
Anticuerpos multivalentes
|
|
GB201005063D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
GB0920127D0
(en)
*
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
|
GB201000467D0
(en)
*
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CA2791930A1
(en)
|
2010-03-11 |
2011-09-15 |
Kerry Louise Tyson |
Pd-1 antibody
|
|
GB201005064D0
(en)
*
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
|
US20130115215A1
(en)
*
|
2010-07-14 |
2013-05-09 |
Hongxing Zhou |
Domain insertion immunoglobulin
|
|
EP3029066B1
(en)
|
2010-07-29 |
2019-02-20 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
JP2014501725A
(ja)
|
2010-11-24 |
2014-01-23 |
グラクソ グループ リミテッド |
Ｈｇｆを標的とする多特異的抗原結合タンパク質
|
|
JP2014501515A
(ja)
|
2010-12-01 |
2014-01-23 |
グラクソ グループ リミテッド |
改良された抗血清アルブミン結合単一可変ドメイン
|
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
|
ME02734B
(me)
|
2011-01-14 |
2017-10-20 |
Ucb Biopharma Sprl |
Antitelo koje vezuje il-17a i il-17f
|
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
|
ES2758884T3
(es)
*
|
2011-06-24 |
2020-05-06 |
Stephen D Gillies |
Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
|
|
PL2731973T3
(pl)
|
2011-07-13 |
2018-04-30 |
Ucb Biopharma Sprl |
Bakteryjny szczep gospodarz wykazujący ekspresję dsbc
|
|
US10752676B2
(en)
|
2011-09-16 |
2020-08-25 |
Ucb Biopharma Sprl |
Neutralising antibodies to the major exotoxins TCDA and TCDB of Clostridium difficile
|
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
US12466897B2
(en)
|
2011-10-10 |
2025-11-11 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
|
SI2776466T1
(sl)
*
|
2011-11-11 |
2017-12-29 |
Ucb Biopharma Sprl |
Protitelesa, ki se vežejo na albumin in njihovi vezavni fragmenti
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
GB201208367D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Biological product
|
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
|
LT2852615T
(lt)
*
|
2012-05-22 |
2019-02-11 |
Bristol-Myers Squibb Company |
Il-17a/f il-23 bispecifiniai antikūnai ir jų panaudojimai
|
|
EP4001307A1
(en)
*
|
2012-12-17 |
2022-05-25 |
Cell Medica Inc. |
Antibodies against il-1 beta
|
|
GB201223276D0
(en)
*
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
|
CN105051069B
(zh)
|
2013-01-14 |
2019-12-10 |
Xencor股份有限公司 |
新型异二聚体蛋白
|
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
|
US9738722B2
(en)
|
2013-01-15 |
2017-08-22 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
|
CN110845618A
(zh)
*
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
EP3421495A3
(en)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
|
WO2015006337A2
(en)
*
|
2013-07-08 |
2015-01-15 |
Nanjingjinsirui Science & Technology Biology Corporation |
Compositions and methods for increasing protein half-life in a serum
|
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
|
JP6422977B2
(ja)
*
|
2013-08-30 |
2018-11-14 |
エイプリルバイオ カンパニー リミテッド |
抗血清アルブミンｆａｂエフェクター部分融合コンストラクト、およびその製造方法
|
|
WO2015048685A1
(en)
*
|
2013-09-30 |
2015-04-02 |
Becton, Dickinson And Company |
Blocking reagent compositions and methods of making and using the same
|
|
SI3021859T1
(en)
|
2013-10-25 |
2018-04-30 |
Psioxus Therapeutics Limited |
Oncolytic adenoviruses equipped with heterologous genes
|
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
|
CA2940242C
(en)
|
2014-02-20 |
2026-01-13 |
H. Lundbeck A/S |
Anti-acth antibodies and use thereof
|
|
KR102497443B1
(ko)
|
2014-03-28 |
2023-02-08 |
젠코어 인코포레이티드 |
Cd38 및 cd3에 결합하는 이중특이적 항체
|
|
EP3126826B1
(en)
|
2014-04-04 |
2020-12-16 |
Mayo Foundation for Medical Education and Research |
Isotyping immunoglobulins using accurate molecular mass
|
|
GB201406608D0
(en)
|
2014-04-12 |
2014-05-28 |
Psioxus Therapeutics Ltd |
Virus
|
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
|
GB201411420D0
(en)
*
|
2014-06-26 |
2014-08-13 |
Ucb Biopharma Sprl |
Antibody constructs
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
|
JP6657195B2
(ja)
*
|
2014-09-19 |
2020-03-04 |
シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ |
Ｌ１３Ｒα２を標的とする共刺激性キメラ抗原レセプターＴ細胞
|
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
|
EP3237449A2
(en)
|
2014-12-22 |
2017-11-01 |
Xencor, Inc. |
Trispecific antibodies
|
|
UA120286C2
(uk)
|
2015-01-08 |
2019-11-11 |
Ґенмаб А/С |
Біспецифічне антитіло проти cd3 і cd20
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP3283522A1
(en)
*
|
2015-04-17 |
2018-02-21 |
Spring Bioscience Corporation |
Antibodies, compositions, and immunohistochemistry methods for detecting c4.4a
|
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
|
JP2018515082A
(ja)
|
2015-04-30 |
2018-06-14 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
代謝障害を処置するための抗ａｐ２抗体及び抗原結合剤
|
|
US10676723B2
(en)
|
2015-05-11 |
2020-06-09 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
CN113940996A
(zh)
|
2015-05-27 |
2022-01-18 |
Ucb生物制药私人有限公司 |
用于治疗神经系统疾病的方法
|
|
CN106188305A
(zh)
*
|
2015-06-01 |
2016-12-07 |
中山大学 |
具有融合至常规Fab片段的单域抗原结合片段的二价抗体
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
PE20221007A1
(es)
|
2015-06-24 |
2022-06-15 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad disenada
|
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
|
MA41670A1
(fr)
|
2015-07-06 |
2018-05-31 |
Ucb Biopharma Sprl |
Anticorps se liant a tau
|
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
WO2017055542A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
|
DK3359688T3
(da)
|
2015-10-05 |
2021-08-23 |
Biogen Ma Inc |
Molekylære signaturer til anvendelse til diagnose og analyse af respons på behandling af autoimmune sygdomme
|
|
RU2754683C2
(ru)
|
2015-10-27 |
2021-09-06 |
Юсб Биофарма Срл |
Способы лечения с использованием анти-il-17a антител
|
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
|
CN108699136B
(zh)
|
2015-12-07 |
2022-03-18 |
Xencor股份有限公司 |
结合cd3和psma的异二聚抗体
|
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
|
JP7328761B2
(ja)
|
2016-01-11 |
2023-08-17 |
インヒブルクス インコーポレイテッド |
多価多重特異性ｏｘ４０結合融合タンパク質
|
|
GB201602414D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Biological materials and uses thereof
|
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
|
JP7133544B2
(ja)
*
|
2016-05-01 |
2022-09-08 |
ユーシービー バイオファルマ エスアールエル |
親和性を操作した血清タンパク質担体結合ドメイン
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
PT3461261T
(pt)
|
2016-05-20 |
2025-07-31 |
Harpoon Therapeutics Inc |
Proteínas de ligação ao cd3 de fragmento variável de cadeia única
|
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
|
CA3026151A1
(en)
|
2016-06-14 |
2017-12-21 |
Xencor, Inc. |
Bispecific checkpoint inhibitor antibodies
|
|
MX2018016265A
(es)
|
2016-06-28 |
2019-07-04 |
Xencor Inc |
Anticuerpos heterodimericos que se unen al receptor 2 de somatostatina.
|
|
CA3030636A1
(en)
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
IL303187A
(en)
|
2016-08-29 |
2023-07-01 |
Akamis Bio Ltd |
Adenovirus with bispecific T cell activator
|
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
PE20240950A1
(es)
|
2016-10-14 |
2024-05-06 |
Xencor Inc |
PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
|
|
WO2018083257A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding transgenes
|
|
WO2018083258A1
(en)
|
2016-11-03 |
2018-05-11 |
Psioxus Therapeutics Limited |
Oncolytic adenovirus encoding at least three transgenes
|
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
|
US11129906B1
(en)
|
2016-12-07 |
2021-09-28 |
David Gordon Bermudes |
Chimeric protein toxins for expression by therapeutic bacteria
|
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
|
GB201621728D0
(en)
|
2016-12-20 |
2017-02-01 |
Ucb Biopharma Sprl |
Methods
|
|
EP3824906A1
(en)
|
2016-12-21 |
2021-05-26 |
Amgen Inc. |
Anti-tnf alpha antibody formulations
|
|
PE20191716A1
(es)
*
|
2017-02-08 |
2019-12-05 |
Bristol Myers Squibb Co |
Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
WO2018162749A1
(en)
|
2017-03-09 |
2018-09-13 |
Genmab A/S |
Antibodies against pd-l1
|
|
WO2018183366A1
(en)
|
2017-03-28 |
2018-10-04 |
Syndax Pharmaceuticals, Inc. |
Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
|
|
WO2018178396A1
(en)
|
2017-03-31 |
2018-10-04 |
Genmab Holding B.V. |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
|
CN115028727A
(zh)
|
2017-05-12 |
2022-09-09 |
哈普恩治疗公司 |
靶向msln的三特异性蛋白质及使用方法
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
JP7537874B2
(ja)
|
2017-05-19 |
2024-08-21 |
シンダックス ファーマシューティカルズ， インコーポレイテッド |
併用療法
|
|
CA3063652A1
(en)
|
2017-06-01 |
2018-12-06 |
Psioxus Therapeutics Limited |
Oncolytic virus and method
|
|
US20200165347A1
(en)
|
2017-06-30 |
2020-05-28 |
Aslan Pharmaceuticals Pte Ltd |
Method of treatment using il-13r antibody
|
|
AU2018291497A1
(en)
|
2017-06-30 |
2020-01-16 |
Xencor, Inc. |
Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
|
|
WO2019025545A1
(en)
|
2017-08-04 |
2019-02-07 |
Genmab A/S |
BINDING AGENTS BINDING TO PD-L1 AND CD137 AND THEIR USE
|
|
PE20200849A1
(es)
|
2017-10-10 |
2020-08-20 |
Numab Therapeutics AG |
Anticuerpo multiespecifico
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP7084990B2
(ja)
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
|
KR20200085828A
(ko)
|
2017-11-08 |
2020-07-15 |
젠코어 인코포레이티드 |
신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
|
|
EP3728302A1
(en)
|
2017-12-19 |
2020-10-28 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
|
EP4495142A3
(en)
|
2017-12-22 |
2025-05-07 |
Argenx BVBA |
Bispecific antigen binding construct
|
|
CN109970856B
(zh)
|
2017-12-27 |
2022-08-23 |
信达生物制药(苏州)有限公司 |
抗lag-3抗体及其用途
|
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
|
GB201802487D0
(en)
|
2018-02-15 |
2018-04-04 |
Argenx Bvba |
Cytokine combination therapy
|
|
WO2019179391A1
(en)
*
|
2018-03-19 |
2019-09-26 |
Wuxi Biologics (Shanghai) Co., Ltd. |
Novel bispecific pd-1/ctla-4 antibody molecules
|
|
WO2019182996A1
(en)
*
|
2018-03-19 |
2019-09-26 |
The Regents Of The University Of California |
Antibody-interferon fusion proteins for enhancing adoptive t cell therapies for the treatment of cancer
|
|
EP3773911A2
(en)
|
2018-04-04 |
2021-02-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
|
MX2020010910A
(es)
|
2018-04-18 |
2021-02-09 |
Xencor Inc |
Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
|
|
KR20210003814A
(ko)
|
2018-04-18 |
2021-01-12 |
젠코어 인코포레이티드 |
IL-15/IL-15Rα Fc-융합 단백질 및 TIM-3 항원 결합 도메인을 함유하는 TIM-3 표적화 이종이량체 융합 단백질
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
PT3806898T
(pt)
|
2018-06-18 |
2025-12-02 |
UCB Biopharma SRL |
Antagonista de gremlin-1 para utilização no tratamento do cancro
|
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
|
BR112021002164A2
(pt)
|
2018-08-13 |
2021-08-03 |
Inhibrx, Inc. |
polipeptídeos de ligação a ox40 e usos dos mesmos
|
|
DK3841120T3
(da)
|
2018-08-21 |
2025-10-20 |
Citryll B V |
Antistoffer, der binder sig til citrullineret histon 2a og/eller 4
|
|
US12460000B2
(en)
|
2018-09-07 |
2025-11-04 |
Itabmed (Hk) Limited |
Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
MX2021003765A
(es)
|
2018-10-03 |
2021-07-15 |
Xencor Inc |
Proteínas il-12 de fusión a fc heterodimérico.
|
|
MX2021003756A
(es)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Composiciones farmaceuticas que comprenden anticuerpos anti cumulo de diferenciacion 37 (cd37) biespecificos.
|
|
KR20260014044A
(ko)
|
2018-10-16 |
2026-01-29 |
유씨비 바이오파마 에스알엘 |
중증근무력증의 치료 방법
|
|
GB201817311D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
GB201817309D0
(en)
|
2018-10-24 |
2018-12-05 |
Ucb Biopharma Sprl |
Antibodies
|
|
MA54139A
(fr)
|
2018-11-06 |
2021-09-15 |
BioNTech SE |
Formulation d'anticorps
|
|
WO2020132810A1
(en)
|
2018-12-24 |
2020-07-02 |
Generon (Shanghai) Corporation Ltd. |
Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
|
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
|
TWI756621B
(zh)
*
|
2019-01-25 |
2022-03-01 |
大陸商信達生物製藥（蘇州）有限公司 |
新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體
|
|
WO2020176478A1
(en)
|
2019-02-25 |
2020-09-03 |
The University Of Chicago |
Methods and compositions for treating inflammatory and autoimmune conditions with ecm-affinity peptides linked to anti-inflammatory agents
|
|
AU2020232605A1
(en)
|
2019-03-01 |
2021-10-21 |
Xencor, Inc. |
Heterodimeric antibodies that bind ENPP3 and CD3
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
CN113416258B
(zh)
*
|
2019-10-24 |
2023-08-29 |
北京免疫方舟医药科技有限公司 |
一种多特异性抗体及其制备方法和用途
|
|
EP3816185A1
(en)
|
2019-11-04 |
2021-05-05 |
Numab Therapeutics AG |
Multispecific antibody directed against pd-l1 and a tumor-associated antigen
|
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
|
CN110950967B
(zh)
*
|
2019-12-13 |
2022-05-13 |
山东民康生物科技有限公司 |
抗人血清白蛋白纳米抗体与il-2融合蛋白及制备方法
|
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
|
CA3167317C
(en)
*
|
2020-02-12 |
2025-05-27 |
Eli Lilly And Company |
CRYSTALLIZATION OF ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS
|
|
US20230151109A1
(en)
|
2020-02-13 |
2023-05-18 |
UCB Biopharma SRL |
Bispecific antibodies against cd9
|
|
US20230125234A1
(en)
|
2020-02-13 |
2023-04-27 |
UCB Biopharma SRL |
Anti cd44-ctla4 bispecific antibodies
|
|
EP4103608A1
(en)
|
2020-02-13 |
2022-12-21 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd137
|
|
US20230096030A1
(en)
|
2020-02-13 |
2023-03-30 |
UCB Biopharma SRL |
Bispecific antibodies against cd9 and cd7
|
|
ES2975410T3
(es)
|
2020-02-13 |
2024-07-05 |
UCB Biopharma SRL |
Anticuerpos biespecíficos que se unen a HVEM y CD9
|
|
IL295448A
(en)
|
2020-02-21 |
2022-10-01 |
Harpoon Therapeutics Inc |
flt3 binding proteins and methods of use
|
|
WO2021164722A1
(zh)
|
2020-02-21 |
2021-08-26 |
江苏恒瑞医药股份有限公司 |
抗il-2抗体、其抗原结合片段及其医药用途
|
|
TWI908779B
(zh)
*
|
2020-03-17 |
2025-12-21 |
美商西雅圖免疫公司 |
引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法
|
|
CA3168613A1
(en)
|
2020-03-18 |
2021-09-23 |
Genmab A/S |
Antibodies binding to b7h4
|
|
CA3175034A1
(en)
|
2020-03-27 |
2021-09-30 |
UCB Biopharma SRL |
Autonomous knob domain peptides
|
|
CN113461824A
(zh)
*
|
2020-03-31 |
2021-10-01 |
普米斯生物技术(珠海)有限公司 |
一种构建多特异性抗体的平台
|
|
CA3176436A1
(en)
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
|
CN115397860B
(zh)
|
2020-05-14 |
2025-06-13 |
江苏恒瑞医药股份有限公司 |
抗cd25抗体、其抗原结合片段及其医药用途
|
|
US11919956B2
(en)
|
2020-05-14 |
2024-03-05 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
|
|
EP3915580A1
(en)
|
2020-05-29 |
2021-12-01 |
Numab Therapeutics AG |
Multispecific antibody
|
|
US20230220111A1
(en)
|
2020-07-02 |
2023-07-13 |
Beijing Tuo Jie Biopharmaceutical Co. Ltd. |
Anti-fxi/fxia antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
|
|
BR112023001359A2
(pt)
|
2020-07-27 |
2023-02-14 |
Tuojie Biotech Shanghai Co Ltd |
Conjugado de anticorpo-fármaco anti-cd79b, método de preparação do mesmo e uso farmacêutico do mesmo
|
|
CN116194477A
(zh)
|
2020-08-06 |
2023-05-30 |
生物技术欧洲股份公司 |
冠状病毒s蛋白的结合剂
|
|
GB202012326D0
(en)
|
2020-08-07 |
2020-09-23 |
Citryll B V |
Diagnostic
|
|
JP7773528B2
(ja)
|
2020-08-19 |
2025-11-19 |
ゼンコア インコーポレイテッド |
抗ｃｄ２８組成物
|
|
US20240034812A1
(en)
|
2020-09-10 |
2024-02-01 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
JP2023541858A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
CN116348494A
(zh)
|
2020-10-13 |
2023-06-27 |
阿尔米雷尔有限公司 |
双特异性分子和使用其的治疗方法
|
|
JP2023547795A
(ja)
|
2020-10-15 |
2023-11-14 |
ユーシービー バイオファルマ エスアールエル |
Ｃｄ４５を多量体化する結合分子
|
|
EP3988568A1
(en)
|
2020-10-21 |
2022-04-27 |
Numab Therapeutics AG |
Combination treatment
|
|
WO2022089767A1
(en)
|
2020-11-02 |
2022-05-05 |
UCB Biopharma SRL |
Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
|
|
KR20230118128A
(ko)
|
2020-12-07 |
2023-08-10 |
유씨비 바이오파마 에스알엘 |
인터루킨-22에 대한 항체
|
|
EP4255926A1
(en)
|
2020-12-07 |
2023-10-11 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
|
KR20230166075A
(ko)
|
2021-02-02 |
2023-12-06 |
누맙 세러퓨틱스 아게 |
Ror1 및 cd3에 대한 특이성을 가지는 다중 특이적 항체
|
|
GB202102227D0
(en)
|
2021-02-17 |
2021-03-31 |
UCB Biopharma SRL |
Antibodies
|
|
CA3212665A1
(en)
|
2021-03-09 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and cldn6
|
|
KR20230154311A
(ko)
|
2021-03-10 |
2023-11-07 |
젠코어 인코포레이티드 |
Cd3 및 gpc3에 결합하는 이종이량체 항체
|
|
JP2024518724A
(ja)
|
2021-04-25 |
2024-05-02 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 |
抗ｍａｓｐ２抗体、その抗原結合断片および医薬用途
|
|
JP2024516305A
(ja)
|
2021-05-03 |
2024-04-12 |
ユーシービー バイオファルマ エスアールエル |
抗体
|
|
EP4085973A1
(en)
|
2021-05-04 |
2022-11-09 |
Citryll B.V. |
Inhibition of eosinophil extracellular traps
|
|
MX2023013021A
(es)
|
2021-05-04 |
2024-02-12 |
Citryll B V |
Inhibicion de trampas extracelulares.
|
|
EP4334359A1
(en)
|
2021-05-07 |
2024-03-13 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
|
|
BR112023027006A2
(pt)
|
2021-06-21 |
2024-03-12 |
BioNTech SE |
Método para reduzir ou prevenir a progressão de um tumor ou tratar um câncer em um sujeito, e, agente de ligação
|
|
BR112023026111A2
(pt)
|
2021-06-28 |
2024-03-05 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Anticorpo anti-cd40, fragmento de ligação ao antígeno e uso médico do mesmo
|
|
WO2023285878A1
(en)
|
2021-07-13 |
2023-01-19 |
Aviation-Ophthalmology |
Methods for detecting, treating, and preventing gpr68-mediated ocular diseases, disorders, and conditions
|
|
CN113527503A
(zh)
*
|
2021-07-27 |
2021-10-22 |
福建医科大学 |
一种用于类风湿性关节炎的抗VEGF和TNF-α双特异性纳米抗体融合蛋白
|
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
|
CN117642424A
(zh)
|
2021-08-25 |
2024-03-01 |
江苏恒瑞医药股份有限公司 |
一种含融合蛋白的药物组合物
|
|
CA3231320A1
(en)
|
2021-09-15 |
2023-03-23 |
Zhiliang CAO |
Protein specifically binding to pd-1 and pharmaceutical use thereof
|
|
US11814437B2
(en)
|
2021-10-08 |
2023-11-14 |
Genmab A/S |
Antibodies binding to CD30 and CD3
|
|
EP4183800A1
(en)
|
2021-11-19 |
2023-05-24 |
Medizinische Hochschule Hannover |
Novel sars-cov-2 neutralizing antibodies
|
|
CN118510815A
(zh)
|
2022-02-11 |
2024-08-16 |
江苏恒瑞医药股份有限公司 |
免疫缀合物及其用途
|
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
|
GB202205200D0
(en)
|
2022-04-08 |
2022-05-25 |
Ucb Biopharma Sprl |
Combination with chemotherapy
|
|
GB202205203D0
(en)
|
2022-04-08 |
2022-05-25 |
UCB Biopharma SRL |
Combination with inhibitor
|
|
WO2024038095A1
(en)
|
2022-08-16 |
2024-02-22 |
Iome Bio |
NOVEL ANTI-RGMb ANTIBODIES
|
|
EP4580753A1
(en)
|
2022-08-31 |
2025-07-09 |
Washington University |
Alphavirus antigen binding antibodies and uses thereof
|
|
GB202214756D0
(en)
|
2022-10-07 |
2022-11-23 |
Univ Oxford Innovation Ltd |
Product
|
|
GB202216284D0
(en)
|
2022-11-02 |
2022-12-14 |
Ucl Business Ltd |
Self-regulation
|
|
EP4626549A1
(en)
|
2022-11-28 |
2025-10-08 |
UCB Biopharma SRL |
Treatment of fibromyalgia
|
|
EP4643877A1
(en)
|
2022-12-28 |
2025-11-05 |
Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Composition of cd40-binding molecule and pharmaceutical use thereof
|
|
EP4681729A1
(en)
|
2023-03-15 |
2026-01-21 |
Shanghai Mabgen Biotech Ltd. |
Pharmaceutical composition containing pd-1/pvrig/tigit binding protein and medical use thereof
|
|
EP4442705A1
(en)
|
2023-04-03 |
2024-10-09 |
Citryll B.V. |
Dosage
|
|
TW202506178A
(zh)
|
2023-04-05 |
2025-02-16 |
丹麥商珍美寶股份有限公司 |
包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物
|
|
US12351650B2
(en)
|
2023-06-30 |
2025-07-08 |
Genmab A/S |
Antibodies binding to fibroblast activation protein alpha and death receptor 4
|
|
AU2024323336A1
(en)
*
|
2023-08-15 |
2026-02-26 |
Minghui Pharmaceutical (Hangzhou) Limited |
Single-domain antibody specifically binding to cdcp1 and use thereof
|
|
WO2025056180A1
(en)
|
2023-09-15 |
2025-03-20 |
BioNTech SE |
Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists
|
|
AR133903A1
(es)
*
|
2023-09-22 |
2025-11-12 |
Ablynx Nv |
Agentes de unión de albúmina bi- y multivalentes
|
|
GB202316779D0
(en)
|
2023-11-01 |
2023-12-13 |
Ucl Business Ltd |
Antigen binding protein
|
|
GB202318703D0
(en)
|
2023-12-07 |
2024-01-24 |
Citryll B V |
Diagnostic agent
|
|
GB202318820D0
(en)
|
2023-12-08 |
2024-01-24 |
UCB Biopharma SRL |
Antibodies
|
|
WO2025133290A1
(en)
|
2023-12-21 |
2025-06-26 |
Temper Bio |
Protein for immune regulation
|
|
TW202540204A
(zh)
|
2024-01-26 |
2025-10-16 |
西班牙商阿爾米雷爾有限公司 |
雙特異性分子及使用其的治療方法
|
|
GB202403366D0
(en)
|
2024-03-08 |
2024-04-24 |
Univ Oxford Innovation Ltd |
Product
|
|
WO2025196217A1
(en)
|
2024-03-21 |
2025-09-25 |
UCB Biopharma SRL |
Treatment of tauopathies with tau-binding antibodies
|
|
WO2025238133A1
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Multispecific antibody with binding specificity for il-11 and il-17
|
|
WO2025238135A2
(en)
|
2024-05-17 |
2025-11-20 |
UCB Biopharma SRL |
Antibody with binding specificity for il-11
|
|
WO2026027660A1
(en)
|
2024-08-02 |
2026-02-05 |
UCB Biopharma SRL |
Formulations of anti-gremlin-1 antibodies
|